RxDoctor Payments Data

Jeremie Young, MD

Emergency Medicine · Macclenny, FLNPI 1003912635

Payments from drug & device makers

$472in general payments, 2019–2025

Across 19 payments — averaging $24.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$157
  • Pacira Pharmaceuticals Incorporated$125
  • Corcept Therapeutics$27
  • Sanofi-aventis U.S. LLC$25
  • Merck$22
  • Amgen$22
  • plus $95 from 6 others

What the payments were for

  • Food & beverage$472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$472 in reported general payments places this provider in the 80th percentile of 3,289 emergency medicine providers in Florida.

See all emergency medicine providers in Florida

Medicare billing

Part B allowed, 2024
$51,476
Medicare patients
263
Services billed
490

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban225$84,893
OzempicSemaglutide39$40,464
JardianceEmpagliflozin18$15,803
JanuviaSitagliptin Phosphate33$15,601
Lagevrio (Eua)Molnupiravir17$14,805
TrulicityDulaglutide13$12,769
Breo ElliptaFluticasone/Vilanterol22$12,142
EntrestoSacubitril/Valsartan21$7,262
XareltoRivaroxaban21$7,179
ArexvyRsvpref3 Antigen/As01e/Pf21$6,396
TradjentaLinagliptin33$6,026
Janumet XrSitagliptin Phos/Metformin Hcl26$4,692
Sucralfate38$4,476
Potassium Chloride218$4,310
AlrexLoteprednol Etabonate12$3,939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Lagevrio (Eua), Janumet Xr$22$35,09976 claims
NovartisEntresto$14$7,26221 claims
AbbVieLumigan$157$3,37512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,289 emergency medicine providers in Florida.

Other emergency medicine in Macclenny

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →